A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer

This multi-center Phase II study evaluated lapatinib, pazopanib, and the combination in patients with relapsed HER2+ inflammatory breast cancer. In Cohort 1, 76 patients were randomized 1:1 to receive lapatinib 1,500 mg + placebo or lapatinib 1,500 mg + pazopanib 800 mg (double-blind) once daily unt...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Cristofanilli, Massimo, Johnston, Stephen R. D., Manikhas, Alexey, Gomez, Henry L., Gladkov, Oleg, Shao, Zhimin, Safina, Sufia, Blackwell, Kimberly L., Alvarez, Ricardo H., Rubin, Stephen D., Ranganathan, Sulabha, Redhu, Suman, Trudeau, Maureen E.
Materialtyp: Artigo
Språk:Inglês
Publicerad: Springer US 2012
Ämnen:
Clinical Trial
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC3539065/
https://ncbi.nlm.nih.gov/pubmed/23239151
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-012-2369-x
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk